EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische Studie

A multicentre prospective phase II study of rituximab combined with bortezomib, lenalidomide and dexamethasone, followed by lenalidomide maintenance (R‐ VRD ) in patients with Waldenström's macroglobulinaemia ( KMM1803 )

Sung-Hoon Jung, Dajung Kim, Je-Jung Lee, Kihyun Kim, Chang-Ki Min, Jae Hoon Lee, Won Sik Lee, Ji Hyun Lee, Gyeong Won Lee, Min Kyoung Kim, Ho-Jin Shin, Hyo Jung Kim und 2 weitere

British Journal of Haematology · 2026

DOI: 10.1111/bjh.70261 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift British Journal of Haematology, 2026. Verfasst von Sung-Hoon Jung und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Hwasun, Jeollanamdo, Sout…. Hauptthemen laut MEDLINE: Waldenstrom Macroglobulinemia, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 20 Literaturangaben. Gefördert von: Samyang, Celltrion.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Waldenström's macroglobulinaemia (WM) has heterogeneous clinical features and limited standard therapeutic options. Although rituximab‐based combinations and Bruton's tyrosine kinase inhibitors have improved outcomes, challenges like incomplete responses and toxicity remain. This prospective, multicentre, phase II study evaluated the efficacy and safety of rituximab, bortezomib, lenalidomide and dexamethasone (R‐VRD) induction therapy, followed by lenalidomide maintenance in patients with symptomatic WM. Two‐year progression‐free survival (PFS) was the primary end‐point, and the secondary end‐points included overall response rate (ORR), overall survival (OS) and safety. Thirty‐eight patients (median age: 66 years) were enrolled. The ORR was 81.6%, and 18.4% of the patients achieved a complete response (CR). The estimated 2‐year PFS and OS rates were 57.9% and 94.7%, respectively, after a median follow‐up of 38.5 months. Notably, responses deepened during lenalidomide maintenance, and 16 experienced further response improvement during the maintenance phase. The most common adverse events were Grade 3–4 haematological toxicities, particularly neutropenia, but they were manageable. Peripheral neuropathy and rash were generally mild. Patients achieving a CR showed no disease progression within 2 years, emphasizing the deep responses' prognostic value. R‐VRD induction, followed by lenalidomide maintenance, demonstrated high efficacy and an acceptable safety profile against symptomatic WM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Waldenstrom MacroglobulinemiaAntineoplastic Combined Chemotherapy ProtocolsHumansLenalidomideAgedMaleDexamethasoneFemaleBortezomibRituximabMiddle AgedProspective StudiesAged, 80 and overAdultTreatment Outcome

Stichwörter der Autor:innen

Waldenström's macroglobulinaemiabortezomiblenalidomidemaintenancerituximabsurvival

Substanzen

LenalidomideDexamethasoneBortezomibRituximab

Autor:innen und Institutionen

  • Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Hwasun, Jeollanamdo, South Korea.
  • Department of Internal Medicine, Kosin University College of Medicine, Busan, South Korea.
  • Department of Medicine, Samsung Medical Center, Sunkyunkwan University School of Medicine, Seoul, South Korea.
  • Department of Internal Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea.
  • Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, South Korea.
  • Department of Internal Medicine, Inje University Busan Paik Hospital, Busan, South Korea.

ORCID-Profile: Ho Sup Lee

Förderung

  • Samyang
  • Celltrion

Zitieren

APA

Jung, S. H., Kim, D., Lee, J. J., Kim, K., Min, C. K., Lee, J. H., Lee, W. S., Lee, J. H., Lee, G. W., Kim, M. K., Shin, H. J., Kim, H. J., Yi, J. H., & Lee, H. S. (2026). A multicentre prospective phase II study of rituximab combined with bortezomib, lenalidomide and dexamethasone, followed by lenalidomide maintenance (R‐ VRD ) in patients with Waldenström's macroglobulinaemia ( KMM1803 ). British Journal of Haematology. https://doi.org/10.1111/bjh.70261

Vancouver

Jung SH, Kim D, Lee JJ, Kim K, Min CK, Lee JH, et al. A multicentre prospective phase II study of rituximab combined with bortezomib, lenalidomide and dexamethasone, followed by lenalidomide maintenance (R‐ VRD ) in patients with Waldenström's macroglobulinaemia ( KMM1803 ). British Journal of Haematology. 2026. doi:10.1111/bjh.70261

BibTeX
@article{Jung2026,
  author = {Jung, Sung-Hoon and Kim, Dajung and Lee, Je-Jung and Kim, Kihyun and Min, Chang-Ki and Lee, Jae Hoon and Lee, Won Sik and Lee, Ji Hyun and Lee, Gyeong Won and Kim, Min Kyoung and Shin, Ho-Jin and Kim, Hyo Jung and Yi, Jun Ho and Lee, Ho Sup},
  title = {A multicentre prospective phase II study of rituximab combined with bortezomib, lenalidomide and dexamethasone, followed by lenalidomide maintenance (R‐ VRD ) in patients with Waldenström's macroglobulinaemia ( KMM1803 )},
  journal = {British Journal of Haematology},
  year = {2026},
  doi = {10.1111/bjh.70261}
}
Kostenlos starten →